These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23262994)

  • 1. Factor VIII haplotypes in severe hemophilia A patients in India.
    Pinto P; Ghosh K; Shetty S
    Ann Hematol; 2013 Jul; 92(7):999-1000. PubMed ID: 23262994
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitors of factor VIII in black patients with hemophilia.
    Viel KR; Ameri A; Abshire TC; Iyer RV; Watts RG; Lutcher C; Channell C; Cole SA; Fernstrom KM; Nakaya S; Kasper CK; Thompson AR; Almasy L; Howard TE
    N Engl J Med; 2009 Apr; 360(16):1618-27. PubMed ID: 19369668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Blood Cells Mol Dis; 2014 Sep; 53(3):161-3. PubMed ID: 24824129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor development in haemophilia A patients with inversion of the intron 22 of the factor VIII gene.
    Tizzano EF; Altisent C; Domènech M; Cornet M; Tusell J; Baiget M
    Thromb Haemost; 1996 Jul; 76(1):125-6. PubMed ID: 8819266
    [No Abstract]   [Full Text] [Related]  

  • 6. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.
    Haghpanah S; Sahraiian M; Afrasiabi A; Enayati S; Peyvandi F; Karimi M
    Haemophilia; 2011 Sep; 17(5):820-1. PubMed ID: 21371201
    [No Abstract]   [Full Text] [Related]  

  • 7. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of factor VIII in hemophilia.
    Lacroix-Desmazes S; Dimitrov JD; Repesse Y
    N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
    [No Abstract]   [Full Text] [Related]  

  • 9. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 10. Pattern of factor VIII inhibitors in patients with hemophilia A in the north east of Iran.
    Modaresi AR; Torghabeh HM; Pourfathollah AA; Shooshtari MM; Yazdi ZR
    Hematology; 2006 Jun; 11(3):215-7. PubMed ID: 17325965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII haplotypes frequencies in Tunisian hemophiliacs A.
    Elmahmoudi H; Belhedi N; Jlizi A; Zahra K; Meddeb B; Ben Ammar Elgaaied A; Gouider E
    Diagn Pathol; 2011 Jun; 6():54. PubMed ID: 21682900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A close insight to factor VIII inhibitor in the congenital hemophilia A.
    Tabriznia-Tabrizi S; Gholampour M; Mansouritorghabeh H
    Expert Rev Hematol; 2016 Sep; 9(9):903-13. PubMed ID: 27367203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin.
    Santagostino E; Gringeri A; Tagliavacca L; Mannucci PM
    Thromb Haemost; 1995 Aug; 74(2):619-21. PubMed ID: 8584995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP; Rice KM; Savidge GF
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII.
    Oldenburg J; Ivaskevicius V; Schröder J; Müller CR; Ganguly A
    Thromb Haemost; 2006 May; 95(5):903-5. PubMed ID: 16676088
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.